First quarter 2023 Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURI ...

Qiagen N.V. (NYSE:QGEN) Q4 2022 Earnings Conference Call February 8, 2023 9:00 AM ET Company Participants John Gilardi - Vice President, Head of Corporate Communications & Investor Relations Thierry Bernard - Chief Executive Officer Roland Sackers - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Aisyah Noor - Morgan Stanley Odysseas Manesiotis - Berenberg Derik De Bruin - Bank of America Matt Sykes - Goldman Sachs Andrew Brackmann - William Blair Falko Friedrichs - Deutsche Ba ...

Forward looking and intended use statements Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. In this presentation, adjusted results include adjusted net sales, adjusted gross income, adjusted net income, adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted operating margin, adjusted net income be ...

Qiagen N.V. (NYSE:QGEN) Q3 2022 Results Conference Call November 8, 2022 9:00 AM ET Company Participants John Gilardi - VP, Corporate Communications & IR Thierry Bernard - CEO Roland Sackers - CFO Conference Call Participants Odysseas Manesiotis - Berenberg Casey Woodring - JPMorgan Derik De Bruin - Bank of America Falko Friedrichs - Deutsche Bank Hugo Solvet - BNP Paribas Ed Ridley-Day - Redburn Operator Ladies and gentlemen, thank you for standing by. I am Perry, your PGI call operator. Welcome, and thank ...

Making improvements in life possible Investor resource book Third quarter 2022 Sample to Insight Forward looking and intended use statements Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These s ...

Financial Data and Key Metrics Changes - Net sales for Q2 2022 reached $544 million at constant exchange rates (CER), a decline of 4% compared to the same period in 2021, driven by a 10% CER growth in non-COVID product sales [11][20] - Adjusted diluted earnings per share (EPS) for Q2 were $0.53 CER, exceeding the outlook of at least $0.46 [12][34] - The company expects full-year sales of at least $2.2 billion and adjusted EPS of at least $2.30 CER, reflecting an increase from previous guidance [15][54] Business Line Data and Key Metrics Changes - Non-COVID product sales grew by 10% CER, representing over 80% of total sales, while COVID-19-related solutions saw a 39% decline in sales [11][19] - Sample technologies, accounting for about one-third of total sales, experienced an overall decline of 7% CER due to reduced COVID testing demand, but non-COVID sales were up 8% CER [22][23] - Diagnostic Solutions, representing about 30% of total sales, saw a 9% increase driven by the QuantiFERON test for tuberculosis [24] - The PCR/Nucleic acid amplification product group remained stable, with double-digit CER growth in non-COVID testing products [25] - The Genomics/NGS product group faced a 23% decline in sales at CER, but excluding prior genomic technology sales, it was up 2% CER [26] Market Data and Key Metrics Changes - The Asia Pacific region showed solid sales growth, with China experiencing low-single-digit CER growth driven by non-COVID demand [28][102] - The Americas region saw overall sales down 1% CER, but non-COVID product groups grew at double-digit rates [30] - Europe, Middle East, and Africa region sales declined by 10% CER due to reduced COVID testing, although some countries maintained double-digit growth [31][103] Company Strategy and Development Direction - The company is focused on its five pillars of growth, with ongoing investments in R&D and marketing to support these areas [16][54] - A conservative view on COVID testing demand is maintained, with a focus on strengthening the core business for sustainable growth [16][60] - The strategy emphasizes a balance between customer segments and geographic regions, aiming for double-digit growth in non-COVID portfolios [61] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's robustness despite macroeconomic challenges, citing proactive measures taken during the pandemic [8][9] - The company is prepared for inflationary pressures and supply chain constraints, having strengthened its supply chain over the past two years [88][112] - Future growth is expected to be driven by a return to normal lab activities and increased R&D spending [91][92] Other Important Information - Operating cash flow increased by 33% to $379 million in the first half of 2022, while free cash flow rose by 63% [35][36] - Total consolidated net debt decreased to $625 million as of June 30, 2022, from $877 million at the end of 2021 [37] Q&A Session Summary Question: Dynamics of non-COVID related sales - Management indicated that non-COVID sales growth is driven by a combination of increased installed base and a return to normal lab activities, with significant contributions from systems like QIAstat and NeuMoDx [64][66][68] Question: Performance of PCR and digital PCR - Digital PCR is seeing strong growth with over 1,000 systems installed, while non-COVID PCR applications are also growing substantially as labs return to pre-COVID consumption patterns [74][76][80] Question: Impact of macroeconomic conditions on guidance - The company has factored in current inflation and geopolitical tensions into its guidance, maintaining a conservative view on COVID sales while expecting continued growth in non-COVID areas [84][86][90] Question: Supply chain issues - Management noted that while no specific product is severely impacted, logistics and raw material supply issues are being managed effectively, with increased inventory levels helping to mitigate disruptions [108][112] Question: Regional performance insights - Growth in China is primarily driven by non-COVID products, while Europe shows mixed results with some countries performing well despite COVID headwinds [99][103]

Q2 2022 results Solid results with 10% CER sales growth in non-COVID portfolios Forward looking and intended use statements Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be, deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any ...

Financial Data and Key Metrics Changes - Net sales for Q1 2022 grew 15% at constant exchange rates (CER) to $628 million compared to the same period in 2021, exceeding the outlook of at least 7% growth CER [12][11] - Adjusted earnings per share (EPS) for Q1 2022 increased to $0.83 CER, surpassing the outlook of at least $0.72 [13][11] - Operating cash flow rose 61% to $207 million, while free cash flow more than doubled to $178 million compared to Q1 2021 [14][35] Business Line Data and Key Metrics Changes - Non-COVID product sales grew 14% CER, while COVID-19 related product sales saw an 18% CER growth, driven by Omicron outbreaks in Europe [12][18] - Consumables and related revenues increased 17% CER, representing 89% of total sales, while instrument sales rose slightly by 2% CER [19][20] - Sales in Diagnostic Solutions rose 21% CER, with QuantiFERON sales increasing by 41% CER to $78 million [23][12] Market Data and Key Metrics Changes - EMEA region sales grew 24% CER, with strong performance in Germany, Spain, the Netherlands, and the UK [27] - Asia Pacific, Japan region also saw a solid growth of 25% CER, with China growing above 10% CER [27] - In the Americas, sales rose 4% CER, with single-digit growth in the U.S. and Brazil, while sales in Mexico declined [28] Company Strategy and Development Direction - The company has increased its outlook for full-year 2022 sales to at least $2.12 billion, driven by double-digit CER growth from non-COVID products [15][49] - Focus remains on advancing non-COVID product groups while maintaining a conservative view on COVID-19 testing demand [15][16] - The company is exploring options for capital deployment, including bolt-on acquisitions, to create greater value for shareholders [39][88] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's robust strategy and execution despite international economic uncertainty [15][11] - The company anticipates a normalization of COVID-related business to pre-COVID growth rates in the second half of the year [70][50] - Management highlighted the importance of maintaining strong profitability and cash flow to support future growth [14][57] Other Important Information - Adjusted gross margin for Q1 2022 stood at 68.6%, largely unchanged from the previous year [29] - R&D investments declined as a percentage of sales to 7.4%, with a target rate of at least 8% to 9% [30] - The company completed a share repurchase program, buying back 1.9 million shares for $100 million [39] Q&A Session Summary Question: Can you discuss the margin performance and expectations going forward? - Management noted that pricing power helped maintain margins despite inflation-driven costs, and they are reinvesting some proceeds into R&D and marketing [64][66] Question: What is the outlook for QIAstat and its market share? - Management confirmed the target for QIAstat to capture at least 10% of the syndromic market, which is expected to grow at around 15% annually [78][79] Question: What is the capital deployment outlook regarding acquisitions and share buybacks? - Management indicated a balanced approach to capital deployment, focusing on bolt-on acquisitions while continuing share buyback programs [86][90] Question: What is the expected growth for QuantiFERON in 2022? - Management confirmed a double-digit growth expectation for QuantiFERON in 2022, with a strong start in Q1 [112][113] Question: How is the company addressing the decline in non-COVID sample tech? - Management acknowledged a tough comparison in Q1 but expects normalization in growth rates for non-COVID sample tech in the upcoming quarters [120][121]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURI ...